Skip to content

Stoke Therapeutics, Inc. STOK Cash Flow Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
-$50M-144%-$57.93M-453%-$38.35M-45.1%-$23.48M+8.6%$112.88M+528%
$439K-8.0%$405K-23.0%$442K-18.1%$446K-18.6%$477K-15.3%
$8.75M+29.6%$9.85M+37.9%$8.04M+7.3%$7.6M+2.3%$6.75M+24.8%
-$60.58M-146%$131.83M+637%
$353K+132%$232K+452%$132K+28.2%$154K+235%$152K+1,167%
$50.69M+272%-$61.06M$0+100%-$148.48M-68.2%$13.63M+36.5%
$84.33M+6,037%$92.34M+16,157%$3.12M-61.8%$554K-99.5%$1.37M-20.0%
$74.44M-49.3%$0+100%-$18.15M+58.2%-$173.35M-1,264%$146.83M+1,242%
-$60.94M-146%$131.68M+636%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Stoke Therapeutics, Inc. generate?
Stoke Therapeutics, Inc. (STOK) generated $26.4M in operating cash flow over the trailing twelve months.
What is Stoke Therapeutics, Inc.'s free cash flow?
After $871.0K of capital expenditures, Stoke Therapeutics, Inc.'s free cash flow was $25.8M over the trailing twelve months, up 132.0% year over year.
Where does Stoke Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Stoke Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.